Points, EVA Air soar into multi-year collaboration enhancing Infinity MileageLands programme

KUALA LUMPUR, Dec 16 -- Award-winning Taiwanese carrier, EVA Air, and global leader in loyalty commerce, Points, have entered into a new multi-year collaboration to introduce a series of member benefits that will increase customer engagement and generate additional ancillary revenue streams for the carrier via the Infinity MileageLands programme.

The partnership began Nov 11, with the introduction of Purchase Miles, which leverages Points’ Buy solution and enables customers to get to their rewards sooner by buying additional miles at a preferential rate.

According to a statement, a series of additional loyalty solutions designed to offer members even more utility and value when accruing miles will be introduced next year.

EVA Air is also leveraging Points’ industry-leading loyalty marketing expertise and data-driven insights to develop personalised campaigns to the Infinity MileageLands membership base which is expected to drive additional growth for the programme.

A further addition as part of the new partnership is EVA Mileage Mall, a market-leading, earning platform powered by Collinson Valuedynamx.

Customers can shop their favourite brands online and earn additional miles that are credited to their membership accounts via an integration with Points’ Loyalty Commerce Platform.

Chief Executive Officer of Points, Rob MacLean said: “We are extremely pleased to be partnering with EVA Air for the first time, and renewing our longstanding collaboration with Collinson, to help grow and enhance the overall value of the Infinity MileageLands programme.”

“By implementing our loyalty solutions, EVA Air can generate additional membership engagement opportunities together with establishing new revenue streams for the Infinity MileageLands programme.”

With this new collaboration, EVA joins close to 60 of the world’s most well known loyalty programmes who already leverage Points' best-in-class loyalty solutions.

-- BERNAMA

LEDDARTECH TO SHOWCASE CRITICAL SENSING AND PERCEPTION SOLUTIONS ENABLING ADAS AND AUTONOMOUS DRIVING AT CES LAS VEGAS 2022

LeddarTech invites LiDAR manufacturers, Tier 1-2 suppliers, system integrators and automotive OEMs to discover the latest in ADAS and AD sensing and perception technologies at booth 7061 January 5-8 at CES 

QUEBEC, Dec 14 (Bernama-GLOBE NEWSWIRE) -- LeddarTech^®, a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, is pleased to announce its participation at five CES Las Vegas locations, January 5-8 ’22. The LeddarTech Showcase location will demonstrate four new leading solutions that enable OEMs, Tier 1-2 suppliers, system integrators and LiDAR manufacturers to solve critical ADAS and AD sensing and perception challenges across the entire value chain of the automotive, mobility and off-road vehicle markets. In addition, LeddarTech will also be present at four other Ecosystem Partner locations. 

http://mrem.bernama.com/viewsm.php?idm=41932

ADAGIO THERAPEUTICS REPORTS REDUCTION IN IN VITRO NEUTRALIZING ACTIVITY OF ADG20 AGAINST OMICRON SARS-COV-2 VARIANT

Previously Reported In Vitro Data Demonstrating that Individual Omicron Mutations Were Not Associated with ADG20 Escape Do Not Translate to Omicron Authentic and Pseudovirus Assays


WALTHAM, Mass., Dec 15 (Bernama-GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided an update following external in vitro analyses to evaluate neutralizing activity of ADG20 against the Omicron SARS-CoV-2 variant. The in vitro data generated through both authentic and pseudovirus testing of the Omicron variant show a greater than 300-fold reduction in neutralizing activity of ADG20 against Omicron. Additional analyses are ongoing, and the company plans to engage with regulatory and government agencies to assess the role ADG20 can play for the prevention and treatment of COVID-19, particularly as the industry’s understanding of the epidemiology and impact of Omicron and potential new variants develops.

“Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we anticipated that ADG20 would retain neutralizing activity against Omicron, consistent with activity observed in in vitro models with all other known variants of concern,” said Tillman Gerngross, Ph.D., chief executive officer of Adagio. “While the individual mutations present in the Omicron receptor binding domain were not associated with escape from ADG20 in the context of an original strain of the virus, new data show that the combination of mutations present in the Omicron spike protein led to a reduction in ADG20 neutralization that was not suggested by prior data. The continued prevalence of the Delta variant in the U.S. and other countries, evolution of SARS-CoV-2 variants and potential future coronaviruses means a multitude of therapies and approaches are needed. With an expert team committed to advancing antibody solutions that combat this unprecedented pandemic and a strong balance sheet, we’re conducting additional analyses to assess the optimal path forward with ADG20 as both a prophylactic and treatment option for COVID-19.”

ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year with a single injection. In previously disclosed in vitro studies, ADG20 retained activity against prior variants of concern including Alpha, Beta, Delta and Gamma. In addition, in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS-CoV-2 variants, including the Lambda, Mu and Delta plus variants. The safety and efficacy of ADG20 have not been established, and ADG20 is not authorized or approved for use in any country.

Adagio is currently evaluating ADG20 in global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. Based on the in vitro findings related to Omicron, Adagio plans to pause patient recruitment in its Phase 2/3 COVID-19 treatment trial at clinical sites in South Africa, where Omicron has emerged as the dominant variant. Adagio is evaluating next steps for its ADG20 program.

In vitro analyses were also conducted on ADG10, a second mAb in development, which showed minimal neutralizing activity against the Omicron variant in both authentic and pseudovirus neutralization assays.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of future program updates and the initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the additional and ongoing analyses to evaluate the activity of ADG20 against the Omicron variant and the potential of ADG20 to play a role as both a prophylactic and a treatment option for COVID-19; the risk/benefit profile of our product candidates to patients; and the adequacy of our cash, cash equivalents and marketable securities. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 and in Adagio’s future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

SOURCE : Adagio Therapeutics, Inc.

Retrace AV launches paint product, destroying SARS-CoV-2, the COVID-19 virus

 

KUALA LUMPUR, Dec 14 -- Billions of people worldwide are attempting to return to workplaces, schools and social spaces. Governments & business owners need to do everything they can to boost confidence and let consumers know their safety is top priority. 

Retrace AV has launched a new paint product that destroys SARS-CoV-2, the COVID-19 virus within 30 minutes, according to a statement.

Retrace AV  is the future proof solution because its mode of action is not variant specific. It can be added into water-based paint to give 99.99 per cent protection against SARS-CoV-2, the COVID-19 virus.

No training is needed, you can simply pour it in, mix and paint. It is easy to order and store, only 25ml of Retrace AV is needed for each 1 litre of paint. It gets to work as soon as the paint dries.

This means, one topcoat of your chosen paint adds antipathogenic security against bacteria and viruses for many years (tested for 10 years) and its efficacy can be verified annually thereafter, by accredited providers.

Developed by an international team, Retrace AV has been tested to ISO 21702, ISO 22196 and ISO 11607 by independent laboratories, including the UK’s National Health Service (NHS) and UL, a global safety certification company, which has verified its effectiveness against SARS-CoV-2.

Retrace AV Limited, a Retrace Group company, leads the international team of manufacturers and distributors delivering the innovative anti-pathogenic paint additive to the world market.

More details at https://retraceav.com/

-- BERNAMA

THE 8TH SILK ROAD INTERNATIONAL FILM FESTIVAL HELD IN FUZHOU - WINNERS OF THE GOLDEN SILK ROAD AWARDS ANNOUNCED

AsiaNet 93650

^{The 8th Silk Road International Film Festival Opening Ceremony}


FUZHOU, China, Dec. 14, 2021 /Xinhua-AsiaNet/--

From December 8th to 12th, the 8th Silk Road International Film Festival was held in Fuzhou City, Fujian Province, China. The event was sponsored by China Media Group, Fujian Provincial Government and Shaanxi Provincial Government, and organized by the Fujian Film Administration, Fuzhou Municipal Government and CCTV-6 Film Channel.
 
The winners of 8th Golden Silk Road Awards are as follows:
-I Never Cry, for Best Film;
-Celine Sciamma, Director of Petite Maman, for Best Director;
-Gong Zhe was honored as Best Actress for her role in Island Keeper;
-Liu Ye was honored as Best Actor for his performance in Island Keeper;
-Turaj Aslani (Iraq/Syria), for Best First-time Director;
-Lennert Hillege (Netherlands), for Best Cinematography;
-Crossing the Yalu River, for Best Visual Effects;
-The Mole Agent (Chile), for Best Documentary Film; and
-Where Is Anne Frank (Belgium/Luxembourg/France/Netherlands), for Best Animation Film
 
According the Office of Executive Committee (Fuzhou) of the Silk Road International Film Festival, during the five-day Festival, nearly one hundred film professionals from countries and regions along the Silk Road gathered in Fuzhou and discussed the development of the film industry. Movies are used as a tie to promote cultural exchanges between China and the countries and regions along the Belt and Road.
 
Source: Office of Executive Committee (Fuzhou) of the Silk Road International Film Festival
 
Image Attachments Links:
 
   Link: http://asianetnews.net/view-attachment?attach-id=410813
 
   Caption: The 8th Silk Road International Film Festival Opening Ceremony

ADAGENE PRESENTS PRECLINICAL DATA SHOWCASING BEST-IN-CLASS PROFILES FOR ADG153, AN ANTI-CD47 SAFEBODY® AND ADG152, A CD20XCD3 BISPECIFIC T-CELL ENGAGER POWERBODY™

- Posters presented at the 63^rd American Society of Hematology Annual Meeting -


SAN DIEGO and SUZHOU, China, Dec 14 (Bernama-GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE). The data were presented in two poster presentations at the 63^rd American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 11-14, 2021, which are available in the Publications section of the company’s website at www.adagene.com.

“Our novel anti-CD47 antibody and CD20xCD3 bispecific TCE programs successfully leverage SAFEbody technology for precision masking to decouple efficacy from the toxicities that are often associated with therapeutic modalities for these two important targets on the forefront of clinical development for hematologic malignancies,” said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. “Our preclinical evaluation shows the desirable target product profiles of these two transformative programs emerging from our deep, broad and differentiated pipeline. In particular, we are very excited about our highly differentiated anti-CD47 SAFEbody in IgG1 format, which introduces IgG1-mediated effects for potent tumor killing with a compelling safety profile and 8-fold prolonged half-life. Our first POWERbody CD20xCD3 bispecific TCE with precision masking on our tailor-made anti-CD3 arm is highly differentiated, engineered for potent and sustained tumor killing with more than 100-fold cytokine release control and 2-3-fold prolonged half-life in comparison with a benchmarked antibody in clinical development. Together, these two programs highlight the strength of our AI-powered antibody platform, paving the way for explosive growth of our pipeline.”

ADG153 (Anti-CD47 SAFEbody)

Key findings from the poster (#3342) titled “ADG153, an Anti-CD-47 Monoclonal Antibody Prodrug, Has Strong In Vivo Anti-Tumor Activity, Minimal RBC-Related and Antigen Sink Liabilities, and Extended Half Life in Comparison with Benchmark Clinical Antibodies of the Same IgG Subclass” include:

• Given the dose-limiting hematologic toxicity and antigen sink liability associated with current anti-CD47 antibodies in clinical development, Adagene has developed an anti-CD47 SAFEbody with precision masking for preferential binding on CD47 overexpressed on tumor versus normal cells. To realize the full potential of anti-CD47 therapy for both hematologic and solid malignancies, the SAFEbody technology enables IgG1-mediated strong effector functions for potent tumor killing, while minimizing antigen sink and red blood cell (RBC) depletion with an approximately 8-fold prolonged half-life for convenient drug dosing and administration.
• An anti-CD47 ADG153-G4 SAFEbody was designed for benchmarking and evaluated in preclinical studies in comparison with its parental antibody, and analogs of magrolimab (Hu5F9) and lemzoparlimab (TJC4) in IgG4 format with the following findings:
   
  • ADG153-G4 parental antibody and its activated SAFEbody can block the CD47 signal by targeting a unique epitope of CD47 with high affinity and minimal RBC hemagglutination.
  • In preclinical studies in monkeys, ADG153-G4 showed a significantly less decrease in RBCs and hemoglobin at the 10, 30 and 60 mg/kg dose levels compared to Hu5F9 at 10 mg/kg, addressing the hematologic toxicities inherent in current anti-CD47 therapies in development.
  • ADG153-G4 SAFEbody also showed its 8-fold prolonged half-life by overcoming the antigen sink observed with other anti-CD47 therapies in development.
  • Only antibody-dependent cellular phagocytosis (ADCP) effector function was detected for anti-CD47 antibodies in IgG4 isotype via CD47-mediated phagocytosis by macrophage.
• An anti-CD47 ADG153-G1 SAFEbody was designed to maximize tumor killing via IgG1-mediated effector functions unlike many other anti-CD47 therapies in development:
   
  • ADG153-G1 induced potent antibody-dependent cellular cytotoxicity (ADCC); as expected, none was observed for the IgG4 benchmark antibodies.
  • ADG153-G1 induced stronger ADCP activity than the IgG4 benchmark antibodies.
• Preclinical results concluded that the ADG153-G1 can achieve potent anti-CD47 efficacy with a well-tolerated safety profile, providing a strong rationale to advance this candidate into clinic. Currently, no other known anti-CD47 antibodies using the IgG1 isotype are in clinical development.
   
  • Notably, ADG153-G1 was well tolerated at 10 mg/kg, with only an 8 percent decrease in RBCs, compared to a 49 percent decrease with Hu5F9 in IgG4 format. For reference, it has been reported in the literature that another IgG1 anti-CD47 antibody can cause more than a 40 percent decrease in RBCs at 1 mg/kg.
  • After a single intravenous dose, ADG153-G1 demonstrated an approximately 8-fold longer apparent half-life and 5-fold higher area under the curve (AUC) at 10mg/kg than Hu5F9.
• Taken together, these preclinical findings suggest that the ADG153-G1 SAFEbody integrates safety (by precision masking) and efficacy (by IgG1-mediated ADCC and ADCP) into one single modality for a best-in-class product profile, presenting the exciting opportunity to maximize potential of anti-CD47 therapy - ultimately aimed for solid malignancies.

ADG152 (CD20xCD3 POWERbody)

Key findings from the poster (#1204) titled “ADG152, a Novel CD20xCD3 T-Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety” include:

• ADG152 is a bispecific CD20xCD3 T-cell engager POWERbody that integrates SAFEbody precision masking technology to minimize cytokine release syndrome (CRS) and on-target/off-tumor toxicities for an increased therapeutic index.
  • The anti-CD20 arm of ADG152 has enhanced the binding to CD20, while its anti-CD3 arm has tailor made affinity for CD3 using SAFEbody technology.

• At a 100-fold higher dose, ADG152 at 30 mg/kg resulted in significantly less cytokine induction (as measured by IFN-γ and IL-2 levels) than an analog of plamotamab at 0.3 mg/kg.
   
• In preclinical models, ADG152 resulted in dose-dependent anti-tumor activity with almost complete tumor growth inhibition when dosed at 1.5 mg/kg.
   
• ADG152 induced strong and sustained B-cell depletion across different dose levels.
   
• ADG152 also demonstrated improved pharmacokinetics in monkeys versus the plamotamab analog, with approximately a 2-fold longer half-life (7-13 days at 0.3 - 30mg/kg) and approximately an 8-fold higher AUC after a single intravenous injection.

“CRS has been a longstanding challenge of T-cell engagers and has limited the ability to safely provide high levels of activity during initial dosing,” said Stanley Frankel, M.D., a clinical advisor who contributed to development and approval of blinatumomab (Blincyto^®) while working at Micromet and Amgen. “I am encouraged that the preclinical profile of ADG152 offers potential to provide a way to simplify treatment by avoiding step dosing and pretreatment with steroids, while also enhancing efficacy of this POWERbody to engage T-cells to attack tumor targets.”

Both ADG153 and ADG152 are potential Investigational New Drug candidates from Adagene’s growing portfolio of preclinical discovery programs, five of which are in IND-enabling studies. The preclinical data presented at ASH provide a strong rationale for advancing these potentially best-in-class candidates into clinical development.

About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody^®, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: https://investor.adagene.com.

SAFEbody^® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding the potential implications of preclinical results, and Adagene’s advancement of, and anticipated clinical activities, clinical development and regulatory milestones of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene’s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene’s drug candidates; Adagene’s ability to achieve commercial success for its drug candidates, if approved; Adagene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene’s reliance on third parties to conduct drug development, manufacturing and other services; Adagene’s limited operating history and Adagene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene’s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene’s clinical development, commercial and other operations, as well as those risks more fully discussed in the “Risk Factors” section in Adagene’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Internal Contact:
Ami Knoefler
Adagene
650-739-9952
ir@adagene.com

External Contact:
Bruce Mackle
LifeSci Advisors
646-889-1200
bmackle@lifesciadvisors.com 


SOURCE : Adagene, Inc.

QIAOXU - CHINA DOWN VALLEY SEES FEATHER FACTORY TRANSFORMATION

 


KUALA LUMPUR, Dec 13 (Bernama) -- Plot B of Qiaoxu - China Down Valley has been under construction in full swing and multiple large machines have been operated for land leveling, as a down feather factory is planned to be built here.

According to the Publicity Department of Gangnan District, Guigang, the total planned land area of the project is 69618.12 square metres, two production workshops are planned to be built, covering an area of 40,000 square metres.

In April, Plot A was put into production, marking an essential stride in the transformation and upgrading of the down feather industry in Gangnan District, according to a statement.

Qiaoxu down feather industry of Gangnan District, Guigang, Guangxi was flourishing in the 1980s.

For over 40 years, Qiaoxu down feather industry has grown rapidly by gathering the high-quality down resources and relying on the industries with little investment but quick results as well as the flexibility in business and agriculture, laying a foundation for the reputations of ‘Hometown of Down in China’, ‘High-quality Down Production Base in China’, and ‘Excellent Down Feather Industrial Cluster in China’.

The products are sold to Zhejiang, Shanghai, and other regions and countries, including Japan, Korea, the United States and Europe, and the processing volume accounts for 28 per cent of China, 18 per cent of the world.

To consolidate existing advantages, Qiaoxu Town Government and Guangxi Qiaoxu Lotus Down Feather Group Co Ltd have prepared to jointly set up the Project of Qiaoxu - China Down Valley.

This is to build it into a new factory with advanced technology and high value-added products upon standardisation, modernisation and internationalisation, intellectualisation.

The total investment is expected to be RMB1.615 billion, and the building area for the construction is planned to be 46.19 hectares. The Project will be divided into three phases, with a construction period of five years. (RMB100 = RM66.30)

--  BERNAMA

LINTONPHARM ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF CATUMAXOMAB FOR NON-MUSCLE-INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN

GUANGZHOU, China, Dec 2 (Bernama-BUSINESS WIRE) -- LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).

“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”

A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control ^[¹^]. Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.

Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC ^[²^][³^]. Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG ^[³ ^].

About Catumaxomab

Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.

Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114).

About LintonPharm

LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com.
 

[¹]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7

[²]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/

[³ ]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/ 

Contact

U.S. Based Media
Tim Hay
The Grace Communication Group
tim@gracegroup.us

APAC Media:
Mia He
LintonPharm
jingyi.he@lintonpharm.com 

Source : LintonPharm Co., Ltd. 

--BERNAMA

Mary Kay renews commitment to prevent, eliminate gender-based violence

 

KUALA LUMPUR, Nov 25 -- Mary Kay Inc and the Mary Kay Ash Foundation have announced a renewed, joint commitment to the prevention and elimination of gender-based violence by joining the Generation Equality Action Coalition on Gender-Based Violence.

This is in recognition of the upcoming International Day for the Elimination of Violence against Women kicking off the 16 Days of Activism against Gender-Based Violence, according to a statement.

The commitment—which the organisations made public during UN Women’s recent Generation Equality Forum in Paris—is just the latest step the storied beauty brand and its charitable arm have made in the interest of improving the lives of women everywhere.

The Action Coalition on Gender-Based Violence, co-led by UN Women and by the UN Trust Fund to End Violence against Women (UN Trust Fund), among other leaders, is a powerful global movement mobilising governments, international organisations, philanthropies, and the private sector to deliver transformational progress towards the elimination of gender-based violence through four concrete actions.

This includes creating enabling policy, legal and resource environments; scaling up evidence driven prevention programming; scaling up comprehensive, accessible, and quality services for survivors; and, enabling and empowering autonomous girl-led and women’s rights organisations to exercise their expertise.

A goal of the Generation Equality Gender-Based Violence Action Coalition is to have 550 million more women and girls live in countries with laws and policies prohibiting all forms of gender-based violence against women and girls by 2026, among others.

During the Forum, UN Women committed to amplifying support and funding to women’s rights organisations by working with partners to secure a minimum of US$100 million in grants to be allocated through the UN Trust Fund to End Violence against Women (UN Trust Fund) over the next five years. (US$1 = RM4.213)

Last year, Mary Kay Inc and the Mary Kay Ash Foundation joined forces with the United Nations Trust Fund to End Violence against Women (UN Trust Fund) and CARE, two champions of women’s rights, to further their mission to achieve a world free from violence against women.

-- BERNAMA

MILREM ROBOTICS LED IMUGS CONSORTIUM DEMONSTRATES DEPLOYMENT OF UNMANNED SYSTEMS

 

Two THeMIS UGVs during the iMUGS Demonstration. One THeMIS UGV is equipped with an Intelligence, surveillance, and reconnaissance (ISR) payload, Signal Intelligence antenna (SIGINT), Rheinmetall’s Rapid Obscuring System (ROSY) Smoke Grenade Launcher, Bittium’s Vehicular Software Defined Radios), and FN Herstal’s deFNder Light Remote Weapon Station (RWS). The second THeMIS, used as a mule for transporting the squad’s equipment, is equipped with Rantelon’s Improvised Explosive Device (IED) Jammer and Bittium’s Tough SDR Vehicular. (Photo: Business Wire) 

ĀDAŽI, Latvia, Nov 25 (Bernama-BUSINESS WIRE) -- The iMUGS Consortium, in charge of a 32,6 MEUR project developing the European standard unmanned ground system (UGS), demonstrated how defence forces can use tactical 4G/5G communications networks and UGS’ equipped with ISR and signal intelligence payloads, jammers, acoustic sensors, and various other technology to conduct missions. 

The demonstration that was performed in September in Latvia, was led by LMT, a member of the integrated Modular Unmanned Ground System (iMUGS) consortium, with the support of the project coordinator Milrem Robotics and featured an ensemble of different technology.

Latvian National Armed Forces used two Milrem Robotics’ THeMIS Unmanned Ground Vehicles (UGV) during two scenarios to display the benefits of teaming up manned units with unmanned systems.

One THeMIS UGV was equipped with an Intelligence, surveillance, and reconnaissance (ISR) payload, Signal Intelligence antenna (SIGINT) provided by The Electronic Communications Office of Latvia, Rheinmetall’s Rapid Obscuring System (ROSY) Smoke Grenade Launcher, Bittium’s Vehicular Software Defined Radios (Tough SDR Vehicular), and FN Herstal’s deFNder Light Remote Weapon Station (RWS). The RWS integration was part of the demonstration, but not of the iMUGS project itself.

The second THeMIS, used as a mule for transporting the squad’s equipment, was equipped with Rantelon’s Improvised Explosive Device (IED) Jammer and Bittium’s Tough SDR Vehicular.

The units and UGVs used Bittium’s tactical communication network TAC WIN combined with LMT’s commercial 4G and a tactical 5G-SA bubble provided by Bittium and Cumucore.

In addition, Krauss-Maffei Wegmann’s (KMW) Dingo infantry mobility vehicle was used as the command centre from where UGVs were operated in Line of Sight (LOS) and Beyond the Line of Sight (BLOS) mode using Bittium’s SDR radios and to where the ISR and Signal Intelligence sensor feed was relayed and incorporated into LMT’s Battle Management System Viedsargs.

“The displayed scenarios showed that unmanned systems, enhanced with innovative communication systems and various defence technology, can be used for collecting and sharing tactical information, improve situational awareness, decrease troops physical load, and increase force protection,” explained Kuldar Väärsi, CEO of Milrem Robotics.

''For the first time ever, in a special network, a tactical network was connected with a stand-alone 5G network. This allowed communication between units and robots, as well as collecting information from sensors and placing this information into LMT’s Battle Management System "Viedsargs'','' said Ingmars Pukis, Vice President and Member of the Management Board of LMT.

Additional equipment used in the demonstration included: SRC Brasa's NATRIX UGV used for CASEVAC, high-speed First-Person View drone, Vertical Take-off, and Landing UAV STAR, and a gunshot detection and source recognition audio sensor by Riga Technical University (RTU).

The iMUGS project was launched in 2020 to develop a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems. Its goal is to standardize a Europe-wide ecosystem for ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.

The system will use an existing UGV – Milrem Robotics’ THeMIS – and a specific list of payloads.

The project’s progress is displayed during six demonstrations. „So far Milrem Robotics and LMT Innovations have set the bar very high. Which means we have some great things to wait for as the main results of the iMUGS projects are yet to be seen,“ said Martin Jõesaar from the Estonian Center for Defence Investments, the representative of the participating Member States in the iMUGS Project. The next demonstration will take place in Q1 of 2022 in Finland.

iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Bittium, Diehl Defence, dotOcean, GMV Aerospace and Defence, Insta Advance, Krauss-Maffei Wegmann, Latvijas Mobilais Telefons (LMT), NEXTER Systems, Royal Military Academy of Belgium, Safran Electronics & Defense, Sol.One and Talgen Cybersecurity.

Watch the Demo 2 Scenarios here:

https://www.youtube.com/watch?v=-_iLCV3Ob2I

https://www.youtube.com/watch?v=HbK_ixrTuWU 

View source version on businesswire.com: 
https://www.businesswire.com/news/home/52539351/21

Contact

Gert Hankewitz
Milrem Robotics
gert.hankewitz@milrem.com 

Source : Milrem Robotics

--BERNAMA

OAG new Flight Info Alerts soars

KUALA LUMPUR, Nov 17 -- OAG, the world’s leading provider of travel data and insight, has announced the launch of Flight Info Alerts, its new detection and notification product that delivers changes to flight schedules in real-time.

In response to customer demands for a fast and reliable feed which expedites vital changes, it is the only product on the market that enables customers to get instant updates on carrier flight schedules so they can handle data volatility in real-time.

“Alerts is a much-needed solution for our customers who manage bookings or operations and anyone who relies on the accuracy of these vital changes to drive their business.

“Volatility of this data over the last 18 months has become an increasing challenge, so our customers need us to tell them what’s changed in real-time.

“We’re innovating rapidly to meet the changing needs of the travel sector. Our investment in OAG Metis and great tech partnerships with Snowflake and Microsoft Azure enable us to serve the entire ecosystem to scale and serve multiple markets rapidly and efficiently,” said OAG CEO, Phil Callow in a statement.

OAG’s Flight Info Alerts launch is the latest in a wave of new product innovations powered by its new technology platform, OAG Metis, which saw the release of Flight Info Direct, a Snowflake enabled platform to access and integrate ready to query data, earlier this year.

The evolution and ambition of OAG’s Flight Info API continues to gather pace to equip customers with data covering the full flight and booking journey, with the imminent availability of Flight Status Data into the API suite. Access through a singular API enables OAG customers to innovate, react faster and scale quicker.

For more information, visit: www.oag.com

-- BERNAMA

Celltrion secures CHMP positive opinion for regdanvimab (CT-P59) over COVID-19 treatment

KUALA LUMPUR, Nov 15 -- Celltrion Group has announced the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59).

regdanvimab (CT-P59) is a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

The CHMP positive opinion is a scientific recommendation to the European Commission (EC), which authorises marketing approval in the European Union, according to a statement.

“We have accumulated the safety and efficacy data of regdanvimab in the treatment of patients infected with COVID-19 and its associated variant strains, including the more virulent Delta variant,” said Head of Medical and Marketing Division at Celltrion Healthcare, Dr HoUng Kim, Ph.D.

“At Celltrion, we are proud to play our part in tackling the unprecedented global threat of COVID-19 and believe regdanvimab offers an important addition to the treatment arsenal.”

The positive CHMP opinion was supported by data from the global Phase III clinical trial in which Celltrion enrolled more than 1,315 people to evaluate the efficacy and safety of regdanvimab in 13 countries including the US, Spain, and Romania.

Data showed regdanvimab significantly reduced the risk of COVID-19 related hospitalisation or death by 72 per cent for patients at high-risk of progressing to severe COVID-19.

Rolling review of regdanvimab had been initiated by the EMA in February this year and the announcement of the CHMP positive opinion for regdanvimab follows the submission of a marketing authorisation application (MAA) to the EMA seeking approval of regdanvimab in October.

More details at https://www.celltrionhealthcare.com/en-us.

-- BERNAMA

NCSOFT: Lineage W new commercial features 'Game of Thrones' star Kit Harington

 

KUALA LUMPUR, Nov 5 -- NCSOFT, a global premier game developer and publisher, has revealed a new commercial of the company’s multi-platform MMORPG, ‘Lineage W’.

Lineage W’s new TV commercial and digital ad which features ‘Game of Thrones’ star Kit Harington delivering an epic speech to his Blood Brethren before battle, emphasises Lineage’s core values: battle, Blood Pledge, sacrifice, and honour.

According to a statement, the commercial is being aired on TV in selected regions and is available on the official website and Lineage W YouTube.

Lineage W is now available for play in 12 countries and regions, including Korea, Taiwan, Japan, Southeast Asia, and the Middle East.

NCSOFT will expand service regions to North America, South America, Europe, and Russia in the near future. Players can download Lineage W on iOS devices, Android devices, and PC (via PURPLE, NCSOFT’s proprietary PC cross-play service).

-- BERNAMA

MINISTRY OF ENVIRONMENT HOLDING EXHIBITIONS AND SEMINARS AT JAPAN PAVILION AT COP 26

TOKYO, Nov. 5, 2021 /Kyodo JBN-AsiaNet/ --

The Ministry of the Environment, Japan (MOEJ), has set up the Japan Pavilion at the venue of COP 26 (the 26th Conference of the Parties to the United Nations Framework Convention on Climate Change), underway in Glasgow, the United Kingdom, from October 31 to November 12, 2021. The Pavilion provides the opportunity for Japanese stakeholders including companies to organize exhibitions and seminars. MOEJ is also organizing the Virtual Japan Pavilion to showcase technologies and actions online. - Overview of Japan Pavilion at COP 26 During COP 26, MOEJ is operating the Japan Pavilion to hold exhibitions and seminars, as well as the Virtual Japan Pavilion, which showcases technologies and actions, in order to introduce Japan's initiatives and environmental technologies to achieve global and domestic decarbonization. On July 20, 2021, MOEJ issued a call for applications to exhibit advanced decarbonization technologies at the Japan Pavilion, and selected 12 on-site exhibits as well as 33 virtual exhibits (as shown in Attachment 1). In addition, seminars listed in Attachment 2 are being held at the Japan Pavilion. Detailed information for the exhibitions and seminars has been posted on the following website. - COP 26 Japan Pavilion Website: http://copjapan.env.go.jp/cop/cop26/en/index.html Attachment 1: List of Pavilion exhibitions https://kyodonewsprwire.jp/attach/202111022694-O1-QeC4v9P7.pdf Attachment 2: Tentative seminar schedule https://kyodonewsprwire.jp/attach/202111022694-O2-30sBDuM5.pdf Source: Ministry of the Environment --BERNAMA

TESSA THERAPEUTICS ANNOUNCES PRESENTATION OF AUTOLOGOUS AND ALLOGENEIC CELL THERAPY DATA AT 2021 ASH ANNUAL MEETING

Presentations to feature clinical data from a Phase II CD30 CAR-T therapy study and a Phase I CD30 CAR-EBVST therapy study targeting lymphomas

SINGAPORE, Nov 5 (Bernama-GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that data from its ongoing autologous and allogeneic cell therapy studies targeting lymphomas has been accepted for two separate poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition being held from December 11-14, 2021.

The presentations include clinical data from a Phase II multi-center study evaluating safety and efficacy of CD30 CAR-T therapy (TT11) in patients with relapsed / refractory classical Hodgkin Lymphoma (R/R cHL) and another Phase I investigator-initiated study testing allogeneic ‘off-the-shelf’ CD30 CAR EBVST therapy (TT11X) in patients with relapsed / refractory CD30+ lymphoma. Accepted abstracts will also be published online in the November supplemental issue of Blood, a publication of the American Society of Hematology.

Details of Presentations

Title: Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
Session Name: 704. Cellular Immunotherapies: Clinical: Poster III
Abstract: #3847
Presenting Author: Sairah Ahmed, M.D., MD Anderson Cancer Centre
Date, Time and Location: December 13, 2021; 6:00 PM - 8:00 PM ET; Georgia World Congress Center, Hall B5

Title: Safety and efficacy of off-the-shelf CD30.CAR-modified Epstein-Barr virus-specific T cells in patients with CD30-positive lymphoma
Session Name: 704. Cellular Immunotherapies: Clinical: Poster I
Abstract: #1763
Presenting Author: David Hon Quach, Instructor, Center for Gene Therapy, Baylor College of Medicine, Houston, TX
Date, Time and Location: December 11, 2021; 5:30 PM - 7:30 PM ET; Georgia World Congress Center, Hall B5

About TT11 (CD30 CAR-T Therapy)

TT11 is a CAR-T therapy, which harvests a patient’s own T-cells and modifies them by introducing a CD30-directed Chimeric Antigen Receptor (CAR) to target and kill CD30+ cells in classical Hodgkin Lymphoma (cHL). CD30 is a well validated lymphoma target with homogeneous expression in 98% of cHL and a significant proportion of subsets of non-Hodgkin Lymphomas. Clinical data from two Phase 1/2 studies, published last year in the Journal of Clinical Oncology^a, showed TT11 demonstrated strong safety and efficacy as a monotherapy for heavily pre-treated R/R cHL patients. A Phase 2 study was subsequently conducted this year evaluating TT11 among R/R cHL patients, results for which will be presented at 2021 ASH annual meeting.

About TT11X (Allogeneic CD30 CAR-EBVST Therapy)

TT11X is an allogeneic ‘off-the-shelf’ therapy which augments Epstein bar virus-specific T-cells with CD30 CAR technology. The therapy is based on a proprietary allogeneic cell therapy platform developed from decades-long research and development on unique properties of Virus Specific T-cells (VSTs) by Tessa’s Scientific Co-Founder, Dr. Malcolm Brenner, and the team at Baylor College of Medicine. VSTs are highly specialized T cells with the ability to recognize and kill infected cells while activating other parts of the immune system for a coordinated response. Allogeneic VSTs without any form of genetic modification have demonstrated a strong safety profile and efficacy in early trials with minimal risk of GVHD. Preclinical studies have further demonstrated that CD30 targeting potentially helps improve allogeneic cell expansion and persistence. With this platform approach, Tessa aims to overcome the current challenges faced by allogeneic cell therapies and create more efficacious, reliable, and scalable therapies capable of targeting a broad range of cancers.

About Tessa Therapeutics

Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors. Tessa’s lead clinical asset, TT11, is an autologous CD30 targeting CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma (Phase 2). TT11 has been granted RMAT designation by the FDA and PRIME designation by European Medicine Agency. Tessa is also advancing an allogeneic “off-the shelf” cell therapy platform targeting a broad range of cancers in which Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CAR technology to prevent graft rejection. A therapy using this platform is currently the subject of a Phase 1 clinical trial in CD30-positive lymphoma. A third clinical asset evaluates novel combination therapy of HER2-CAR-T cells and binary oncolytic virus in an ongoing Phase 1 study targeting HER2 positive solid tumors. Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility. Tessa’s United States headquarters are in New Jersey. For more information on Tessa, visit www.tessacell.com.

Cautionary Note on Forward Looking Statements

This press release contains forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, to the fullest extent applicable) including, without limitation, with respect to various regulatory filings or clinical study developments of the Company. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the Company’s financial results, the ability to raise capital, dependence on strategic partnerships and licensees, the applicability of patents and proprietary technology, the timing for completion of the clinical trials of its product candidates, whether and when, if at all, the Company’s product candidates will receive marketing approval, and competition from other biopharmaceutical companies. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made, and disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The Company’s products are expressly for investigational use pursuant to a relevant investigational device exemption granted by the U.S. Food & Drug Administration, or equivalent competent body.

References:
a. Ramos et al., J Clin Oncol 2020

Tessa Therapeutics Media Contact
Ritika Khetawat
+65 6384 0755
media@tessacell.com

Source: Tessa Therapeutics Ltd

--BERNAMA

JUNIPER RESEARCH: ROAMING REVENUE LOSSES TO SURPASS $2 BILLION GLOBALLY BY 2026; NECESSITATING NEW CLEARING PROCESSES FOR OPERATORS

BASINGSTOKE, England, Oct 25 (Bernama-BUSINESS WIRE) -- A new Juniper Research study has found operators will lose around $484 million in roaming revenue from the misidentification of roaming data traffic this year. These losses are expected to rise to $2.1 billion by 2026; representing absolute growth of 331%. The report found the inability to distinguish between 4G and 5G data traffic using current standards will result in greater losses as the travel industry returns to pre-pandemic levels and 5G adoption increases.

In response, the new research, Data & Financial Clearing: Emerging Trends, Key Opportunities & Market Forecasts 2021-2026, cited the support by operators for the BCE (Billing & Charging Evolution) protocol as being a key strategy to minimise the extent of revenue leakage. BCE is an end-to-end industry-wide standard defined by the GSMA that introduces new capabilities that identify roaming data traffic over different network technologies.

For more insights, download our free whitepaper: Mobile Roaming & the $2 Billion Revenue Leakage Problem

5G Roaming to Drive Roaming Market Evolution

This issue of misidentifying roaming data will only be exacerbated by the rising number of 5G subscribers roaming internationally. The report forecasts there will be over 200 million 5G roaming connections by 2026; rising from 5 million in 2021. This growth is driven by increasing 5G adoption and a return to pre-pandemic levels of international travel. In response, it urges operators to identify emerging areas of potential revenue leakage by leveraging machine learning in roaming analytics tools to efficiently assess roaming behaviour and data usage.

In addition, the report found to effectively mitigate the growing complexity of clearing processes arising from increased demand for data when roaming, operators must move away from established roaming clearing practices in favour of BCE.

Research author Scarlett Woodford remarked: “By combining BCE with AI-enabled roaming analytics suites, operators will be ideally positioned to deal with the rise in roaming data. Separating roaming traffic by network connectivity is essential to allow operators to charge roaming partners based on latency and download speed, and maximise overall 5G roaming revenue.” 

http://mrem.bernama.com/viewsm.php?idm=41354

Zoho introduces new apps, services in Zoho One

KUALA LUMPUR, Oct 20 -- Zoho Corporation, a leading global technology company, has introduced new apps and services in Zoho One, the operating system for business.

The new release empowers businesses to solve disjointed data challenges and close communications gaps across silos, so organisations can become more productive, adapt more quickly to changing business conditions, and become poised for growth.

According to a statement, Zoho One aims to resolve operational, digitisation, and retention challenges that businesses encounter.

“Unification of a business requires unification of the underlying systems, which can then provide a truly unified experience, internally and externally, along with unified insights. Zoho One was created with this vision and keeps expanding its unbeatable value with new additions and improvements year over year,” said Chief Evangelist at Zoho, Raju Vegesna.

Featuring five new apps, three new services, and seven major platform enhancements, Zoho One helps businesses unify systems, data and teams.

Businesses now have stronger real-time, organisation-wide analytics, connecting the dots between data previously lost across departments, teams, and accounts.

Powered by Zia, Zoho's AI assistant, and Zoho's BI and Analytics Platform, Zoho One allows users to predict and provide insights across the organisation enabling confident decision-making.

The addition of Mobile Application Management (MAM) and Zoho Commerce aim to help businesses better manage operations. With remote work now persistent, Zoho One now includes enterprise-grade Mobile App Management capabilities.

Zoho Commerce enables retailers to easily build online shops with the tools needed to construct a website, accept orders, track inventory, process payments, manage shipping, market their brand, and analyse data.

To help close the distance between employees, employers, and teams, which has widened with remote work, Zoho One delivers solutions that promote stronger collaboration and employee experience to support any mode of work.

More details at www.zoho.com/

-- BERNAMA

Juniper Research announces 2022 Telco Innovation Future Digital Awards opening

KUALA LUMPUR, Oct 21 -- Juniper Research has announced the 2022 Telco Innovation Future Digital Awards are open, with entries closing on Dec 3, before being assessed by Juniper Research’s expert panel of analysts.

The awards will be announced on Jan 25, 2022, according to a statement.

Since 2008, the Future Digital Awards have been awarded to tech companies at the forefront of their respective fields: companies that deliver imaginative and innovative products or services that have the potential to disrupt their ecosystems and provide significant benefits to their target audience.

These awards aim to reward the most innovative vendors and solutions in the fast-paced mobile communications market; following a year of unparalleled innovation.

This year’s Telco Innovation Future Digital Awards cover categories, namely, Enterprise Telco Innovation: Best Carrier Billing Solution (Platinum & Gold); Best Steering of Roaming Solution (Platinum & Gold); Best RCS Provider (Platinum & Gold); and, Best Mobile Video Solution (Platinum), among others.

Under Operator & Network Innovation: Best Digital Transformation Project in Telco (Platinum); Network Virtualisation Innovation of the Year (Platinum & Gold); Best Operator 5G Solution (Platinum & Gold); Best Cellular IoT Initiative (Platinum & Gold); and, Best 5G Roaming Service Provider (Platinum & Gold).

For Security & Fraud Innovation: Best Robocall Mitigation Solution (Platinum & Gold); Best Mobile Identity Solution (Platinum & Gold); Best SMS Firewall (Platinum & Gold); Best Financial Clearing Solution (Platinum & Gold); and, Best Flash Call Authentication Solution (Platinum).

While the rest of the awards focus on products, the Judges’ Choice awards assess people and companies that contribute the most to telecommunications industry, namely Mover & Shaker in Telco Innovation, and, Excellence in Telco Innovation.

Entrants can apply for the awards at https://www.juniperresearch.com/future-digital-awards/telco-innovation.

Juniper Research provides research and analytical services to the global hi-tech communications sector; providing consultancy, analyst reports and industry commentary.

-- BERNAMA